Description
Pentadeca Arginate (PDA)
The newer alternative to BPC-157 — arginate-stabilized for improved stability, similar healing effects.
Pentadeca Arginate (PDA) is a newer 15-amino-acid peptide closely related to BPC-157, but stabilized with an arginate salt
to enhance shelf life and stability. PDA has emerged as a preferred alternative to BPC-157 at many functional medicine
practices, offering similar tissue-repair and anti-inflammatory benefits with better pharmaceutical-grade stability. PDA is
sometimes used in patients who haven’t responded well to BPC-157, or as part of compounding pharmacy formulations where
supply has been an issue.
HOW IT WORKS
Promotes angiogenesis (new blood vessel formation)
Stimulates growth hormone receptor expression on injured cells
Modulates nitric oxide, serotonin, and dopamine pathways
Supports gut lining repair (like BPC-157)
Anti-inflammatory at multiple tissue sites
Arginate salt provides better stability than BPC-157 free acid
WHAT IT’S USED FOR
• Gut repair (IBS, leaky gut, ulcers, GERD)
• Tendon & ligament injuries
• Joint pain & inflammation
• Post-surgical soft tissue recovery
• Muscle injury & chronic strain recovery
• Wound healing (slow-healing, chronic)
• Chronic inflammation & autoimmune flare support
• Alternative for patients with limited BPC-157 access
• Alternative for patients with limited BPC-157 access
DOSING & PROTOCOL
Form Standard dose 250–500 mcg daily, subcutaneous
Injury-focused dose Up to 500 mcg twice daily for acute injury
Cycle pattern 4–6 weeks on, 2-week break, re-evaluate
Injection site Subcutaneous — belly fat or thigh
Administered by Patient self-injection after training, or in-office
Pairs well with TB-500, GHK-Cu, Collagen peptides + Vitamin C
Subcutaneous injection (oral capsule occasionally available)
WHAT PATIENTS REPORT
• Faster injury & gut repair
• Reduced joint & tendon pain
• Calmer digestion & reduced bloating
• Better workout recovery
• Improved overall resilience
• Effective alternative when BPC-157 isn’t available
• Improved stability vs. traditional BPC-157
• Improved stability vs. traditional BPC-157
BEST FOR
Patients seeking BPC-157-like benefits with improved
pharmaceutical stability, those who haven’t responded
to BPC-157, patients with gut healing needs, athletes
with chronic injury recovery, and those wanting a newer
compounded peptide option.
Safety & pharmacy notes: PDA appears to share BPC-157’s favorable safety profile. Possible mild effects: redness at injection site, mild headache, or transient fatigue.
Not recommended in active cancer (promotes angiogenesis), pregnancy, breastfeeding, or known
peptide hypersensitivity.
PDA is not FDA-approved as a commercial drug and is dispensed only through licensed 503A compounding
pharmacies on a per-patient prescription basis. As a newer compound, long-term safety data is still being accumulated.
Initial consultationwith Dr. Thomas required.
www.suresuccesswellness.com
Reviews
There are no reviews yet.